CN112220739B - 一种hpv病毒灭活敷料及其制备方法 - Google Patents
一种hpv病毒灭活敷料及其制备方法 Download PDFInfo
- Publication number
- CN112220739B CN112220739B CN202011102513.5A CN202011102513A CN112220739B CN 112220739 B CN112220739 B CN 112220739B CN 202011102513 A CN202011102513 A CN 202011102513A CN 112220739 B CN112220739 B CN 112220739B
- Authority
- CN
- China
- Prior art keywords
- peptide
- hpv
- dressing
- ganoderan
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 68
- 230000002779 inactivation Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 69
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 41
- 230000008439 repair process Effects 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 239000000419 plant extract Substances 0.000 claims description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 24
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 18
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 18
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 17
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 240000008397 Ganoderma lucidum Species 0.000 claims description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 14
- 229940088598 enzyme Drugs 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 11
- 150000003384 small molecules Chemical class 0.000 claims description 9
- 108010053775 Nisin Proteins 0.000 claims description 8
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical group N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000004309 nisin Substances 0.000 claims description 8
- 235000010297 nisin Nutrition 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 229940107131 ginseng root Drugs 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 44
- 230000006870 function Effects 0.000 abstract description 10
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 8
- 201000010881 cervical cancer Diseases 0.000 abstract description 8
- 239000013543 active substance Substances 0.000 abstract description 5
- 210000002919 epithelial cell Anatomy 0.000 abstract description 4
- 210000002865 immune cell Anatomy 0.000 abstract description 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 63
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 59
- 230000000694 effects Effects 0.000 description 19
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 210000000170 cell membrane Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241001112090 Pseudovirus Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000000415 inactivating effect Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 208000009608 Papillomavirus Infections Diseases 0.000 description 6
- 229940089161 ginsenoside Drugs 0.000 description 6
- 229930182494 ginsenoside Natural products 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 241000341655 Human papillomavirus type 16 Species 0.000 description 5
- 241001071917 Lithospermum Species 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 5
- 229960001231 choline Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 4
- NEZONWMXZKDMKF-SNVBAGLBSA-N Shikonin Chemical compound C1=CC(O)=C2C(=O)C([C@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-SNVBAGLBSA-N 0.000 description 4
- 241000246044 Sophora flavescens Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 201000010153 skin papilloma Diseases 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 3
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- -1 acetyl pachymic acid Chemical compound 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- FAPWSAQOVOBPCP-UHFFFAOYSA-N 7-hydroxy-3-(6-hydroxy-1,3-benzodioxol-5-yl)-2,3-dihydrochromen-4-one Chemical compound C1OC2=CC(O)=CC=C2C(=O)C1C(C(=C1)O)=CC2=C1OCO2 FAPWSAQOVOBPCP-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010026389 Gramicidin Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical group C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- QFJUYMMIBFBOJY-UXZRXANASA-N Panaxatriol Chemical compound C[C@]1([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@]3(C[C@@H](O)[C@H]3C(C)(C)[C@@H](O)CC[C@@]32C)C)C)CCCC(C)(C)O1 QFJUYMMIBFBOJY-UXZRXANASA-N 0.000 description 2
- VIXIMKLMEZTTTC-UHFFFAOYSA-N Panaxatriol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(O)CC34C VIXIMKLMEZTTTC-UHFFFAOYSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 241000972672 Phellodendron Species 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical group O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 235000019206 astragalus extract Nutrition 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 201000004196 common wart Diseases 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 102000006966 enzyme regulator activity proteins Human genes 0.000 description 2
- 108040000578 enzyme regulator activity proteins Proteins 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 229960004905 gramicidin Drugs 0.000 description 2
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 235000019534 high fructose corn syrup Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SOWZKCJTXGPDCN-UHFFFAOYSA-N 3,5-dihydroxy-2-(4-hydroxyphenyl)-7-methoxy-8-(3-methylbut-3-enyl)chromen-4-one Chemical compound OC1=C(OC2=C(C(=CC(=C2C1=O)O)OC)CCC(=C)C)C1=CC=C(C=C1)O SOWZKCJTXGPDCN-UHFFFAOYSA-N 0.000 description 1
- CQSRUKJFZKVYCY-OYLIUYJJSA-N 5alpha-24E-ethylidene-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1C2[C@@H]2CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]2(C)CC1 CQSRUKJFZKVYCY-OYLIUYJJSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 241000388169 Alphapapillomavirus 7 Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 244000249214 Chlorella pyrenoidosa Species 0.000 description 1
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 description 1
- 240000009108 Chlorella vulgaris Species 0.000 description 1
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000000774 Cunila origanoides Species 0.000 description 1
- 235000018274 Cunila origanoides Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- AQASRZOCERRGBL-UHFFFAOYSA-N Dauricine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 235000014866 Dictamnus albus Nutrition 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- BVRYLTBIGIAADD-MRXNPFEDSA-N Isobutylshikonin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-MRXNPFEDSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- YSKVBPGQYRAUQO-UHFFFAOYSA-N Schottenol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 YSKVBPGQYRAUQO-UHFFFAOYSA-N 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 1
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- MXANJRGHSFELEJ-MRXNPFEDSA-N [(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-hydroxy-3-methylbutanoate Chemical compound C1=CC(O)=C2C(=O)C([C@H](OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-MRXNPFEDSA-N 0.000 description 1
- WNFXUXZJJKTDOZ-HNNXBMFYSA-N [(1s)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] acetate Chemical compound C1=CC(O)=C2C(=O)C([C@@H](OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-HNNXBMFYSA-N 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- MXANJRGHSFELEJ-UHFFFAOYSA-N beta:-hydroxy isovaleryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- AQASRZOCERRGBL-ROJLCIKYSA-N dauricine Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@H]2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-ROJLCIKYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- NADCVNHITZNGJU-UHFFFAOYSA-N desmethylanhydroicaritin Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2O)=O)=C1OC=2C1=CC=C(O)C=C1 NADCVNHITZNGJU-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000011436 enzymatic extraction method Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- BVRYLTBIGIAADD-UHFFFAOYSA-N isobutyryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(CC=C(C)C)OC(=O)C(C)C)=CC(=O)C2=C1O BVRYLTBIGIAADD-UHFFFAOYSA-N 0.000 description 1
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PEFNSGRTCBGNAN-QNDFHXLGSA-N luteolin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-QNDFHXLGSA-N 0.000 description 1
- SUTSVCLKBLJSPQ-UHFFFAOYSA-N luteolin 7-glucoside Natural products OC1C(O)C(O)C(CO)OC1C1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SUTSVCLKBLJSPQ-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- WNFXUXZJJKTDOZ-UHFFFAOYSA-N shikonin acetate Natural products C1=CC(O)=C2C(=O)C(C(OC(C)=O)CC=C(C)C)=CC(=O)C2=C1O WNFXUXZJJKTDOZ-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 1
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 1
- 235000008209 xanthohumol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种HPV病毒灭活敷料,其主要的活性物是抗菌肽、去端酶小分子活性肽、灵芝多糖等,通过恢复机体内环境的平衡,调动HPV感染患者上皮细胞、免疫细胞及修复细胞功能,可及时、靶向清除高危HPV病毒及感染细胞,纠正损伤细胞功能,从而防患于未然,预防阻断宫颈癌发生。
Description
技术领域
本发明涉及生物医药技术领域,尤其涉及一种HPV病毒灭活敷料及其制备方法。
背景技术
HPV是人类乳头瘤病毒的缩写,目前发现有一百多种病毒,其中80种是跟人体密切相关。HPV感染人体,其中1型感染人体会导致寻常疣,寻常疣的症状表现在手脚外伤部位会出现丘疹或者结节,HPV3型病毒会导致扁平疣,表现在脸上或者手背出现褐色的扁平丘疹,HPV16型、18型会导致性器官疣,也叫尖锐湿疣。HPV感染人体会出现各种各样的症状。宫颈癌是影响全球妇女的第四大常见癌症,而HPV病毒几乎出现在全部宫颈癌病例之中,同时可以引起其他几种癌症,包括阴道、肛门和口咽等。在HPV的200多种类型中,根据其致癌能力分为低危型(Low-risk human papillomavirus,LR-HPV)与高危型(High-risk humanpapillomavirus,HR-HPV),其中HR-HPV感染类型中的16型与18型是最常见并且致癌能力较强的,它们所引起的感染占宫颈癌病例的70%。
目前常见的抗HPV病毒治疗有以下方法:1.HPV疫苗,疫苗价格在3000~8000元不等,而且仅能覆盖70%左右的宫颈癌,国产疫苗正在开发,进入Ⅲ期临床,另外中国HPV流行性型别数据缺乏,追加接种疫苗的有效性还有待研究;2.干扰素,其主要是通过抑制病毒的复制,控制病情的发展,不能杀灭和清除病毒,停药会出现复发,长期用药会导致产生耐药,使后续治疗更加困难,只能是暂时性的压制体内病毒发展,祛除表面疣体的作用,并不能去除体内的病毒;3.中药,作用机理主要是提高人体正气,兼顾解毒,以达到清除HPV的目的,而非杀死病毒,但是这个方法目前研究的人员很多,并没有确切的理论或者数据支撑,未有规模化上市商品;4.手术治疗,此类方法见效快,但是费用高,且会有一定的风险。
发明内容
为了解决上述问题,本发明的第一方面提供了一种HPV病毒灭活敷料,所述敷料至少包括植物提取物、多肽、赋形剂、水。
作为一种优选的技术方案,所述植物提取物选自苦参提取物、人参根提取物、灵芝提取物、黄芪提取物、黄柏提取物、小球藻提取物、茯苓提取物、紫草提取物中的一种或多种的混合。
作为一种优选的技术方案,所述多肽选自抗菌肽、修复肽、细胞因子模拟肽、酶调节剂、激素肽中的一种或多种的混合。
作为一种优选的技术方案,所述抗菌肽选自昆虫抗菌肽、哺乳动物抗菌肽、两栖动物抗菌肽、植物抗菌肽、细菌抗菌肽中的一种或多种的混合。
作为一种优选的技术方案,所述细菌抗菌肽选自杆菌肽、短杆菌肽、多粘菌肽、乳链菌肽中的一种或多种的混合。
作为一种优选的技术方案,所述抗菌肽中的氨基酸残基个数为20~60个。
作为一种优选的技术方案,所述赋形剂选自壳聚糖、羟乙基纤维素、卡波姆、羟丙基甲基纤维素、明胶、海藻胶中的一种或多种的混合。
作为一种优选的技术方案,按重量份计,所述敷料至少包括植物提取物50~90份、多肽5~15份、赋形剂5~10份、水30~40份。
作为一种优选的技术方案,所述植物提取物与多肽的重量比为(5~10):1。
本发明的第二方面提供了一种如上所述的HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
有益效果:本发明提供了一种HPV病毒灭活敷料,主要的活性物是抗菌肽、去端酶小分子活性肽、灵芝多糖等,通过恢复机体内环境的平衡,调动HPV感染患者上皮细胞、免疫细胞及修复细胞功能,可及时、靶向清除高危HPV病毒及感染细胞,纠正损伤细胞功能,从而防患于未然,预防阻断宫颈癌发生。
附图说明
为了进一步解释说明本发明中提供的一种HPV病毒灭活敷料及其制备方法的有益效果,提供了相应的附图,需要指出的是本发明中提供的附图只是所有附图中选出来的个别示例,目的也不是作为对权利要求的限定,所有通过本申请中提供的附图获得的其他相应图谱均应该认为在本申请保护的范围之内。
图1为本发明实施例1中的HPV病毒灭活敷料对HPV18基因永生化Hela细胞增殖的影响。
图2为HPV病毒的基因组成。
图3为本发明中HPV病毒灭活敷料的作用机理。
具体实施方式
参选以下本发明的优选实施方法的详述以及包括的实施例可更容易地理解本发明的内容。除非另有限定,本文使用的所有技术以及科学术语具有与本发明所属领域普通技术人员通常理解的相同的含义。当存在矛盾时,以本说明书中的定义为准。
如本文所用术语“由…制备”与“包含”同义。本文中所用的术语“包含”、“包括”、“具有”、“含有”或其任何其它变形,意在覆盖非排它性的包括。例如,包含所列要素的组合物、步骤、方法、制品或装置不必仅限于那些要素,而是可以包括未明确列出的其它要素或此种组合物、步骤、方法、制品或装置所固有的要素。
连接词“由…组成”排除任何未指出的要素、步骤或组分。如果用于权利要求中,此短语将使权利要求为封闭式,使其不包含除那些描述的材料以外的材料,但与其相关的常规杂质除外。当短语“由…组成”出现在权利要求主体的子句中而不是紧接在主题之后时,其仅限定在该子句中描述的要素;其它要素并不被排除在作为整体的所述权利要求之外。
当量、浓度、或者其它值或参数以范围、优选范围、或一系列上限优选值和下限优选值限定的范围表示时,这应当被理解为具体公开了由任何范围上限或优选值与任何范围下限或优选值的任一配对所形成的所有范围,而不论该范围是否单独公开了。例如,当公开了范围“1至5”时,所描述的范围应被解释为包括范围“1至4”、“1至3”、“1至2”、“1至2和4至5”、“1至3和5”等。当数值范围在本文中被描述时,除非另外说明,否则该范围意图包括其端值和在该范围内的所有整数和分数。
单数形式包括复数讨论对象,除非上下文中另外清楚地指明。“任选的”或者“任意一种”是指其后描述的事项或事件可以发生或不发生,而且该描述包括事件发生的情形和事件不发生的情形。
说明书和权利要求书中的近似用语用来修饰数量,表示本发明并不限定于该具体数量,还包括与该数量接近的可接受的而不会导致相关基本功能的改变的修正的部分。相应的,用“大约”、“约”等修饰一个数值,意为本发明不限于该精确数值。在某些例子中,近似用语可能对应于测量数值的仪器的精度。在本申请说明书和权利要求书中,范围限定可以组合和/或互换,如果没有另外说明这些范围包括其间所含有的所有子范围。
此外,本发明要素或组分前的不定冠词“一种”和“一个”对要素或组分的数量要求(即出现次数)无限制性。因此“一个”或“一种”应被解读为包括一个或至少一个,并且单数形式的要素或组分也包括复数形式,除非所述数量明显旨指单数形式。
为了解决上述问题,本发明的第一方面提供了一种HPV病毒灭活敷料,所述敷料至少包括植物提取物、多肽、赋形剂、水。
在一些优选的实施方式中,所述植物提取物选自苦参提取物、人参根提取物、灵芝提取物、黄芪提取物、黄柏提取物、小球藻提取物、茯苓提取物、紫草提取物中的一种或多种的混合。
苦参,学名Sophoraflavescens Alt.,味苦,性寒,归心、肝、胃、大肠、膀胱经,具有清热燥湿、杀虫、利尿等功效。苦参根含多种生物碱:d-苦参碱、d-氧化苦参碱、槐花醇l-臭豆碱、l-甲基金雀花碱、l-穿叶赝靛碱及槐果碱,还含黄酮类:黄腐醇、异黄腐醇、3,4’,5-三羟-7-甲氧-8-异戊烯基黄酮、8-异戊烯基山柰酚等;苦参茎、叶含木犀草素-7-葡萄糖甙。在一些优选的实施方式中,所述苦参提取物为苦参碱(CAS号:519-02-8)。
人参,学名Panax ginseng C.A.Meyer,味甘、微苦,性平,归脾、肺、心经,具有大补元气、复脉固脱、补脾益肺、生津、安神等功效。人参根中含人参皂甙0.4%:人参皂甙A、B、C、D、E和F(panaxoside A、B、C、D、E、F)等,人参皂甙A(C42H72O14),为人参皂甙Rg1(ginsenosideRg1),人参皂甙B和C水解后产生人参三醇(panaxatriol)皂甙元,人参皂甙D、E和F水解后得20-表人参二醇(20-epiproto panaxo-diol)皂甙元;还含有少量挥发油,油中主要成份为人参烯(panacen,C15H24)0.072%。人参乙醚提取物的低沸点部分分离出β-榄香烯(β-elemene,C15H24),高沸点部分分离出人参炔醇(panaxynol,C17H26O)。此外尚含有单糖类:葡萄糖、果糖、蔗醣,三种三糖:葡萄糖-果糖-果糖、三聚葡萄糖,葡萄糖-葡萄糖-果糖,人参酸(为软脂酸、硬脂酸及亚油酸的混和物),多钟维生素(B1、B2、菸酸、菸酰胺、泛酸),多种氨基酸、胆碱、酶(麦芽糖酶、转化酶、酯酶),精胺(spermine)及胆胺(cholamine)。
灵芝,学名GanodermaLucidum Karst,味甘,性平,归心、肺、肝、肾经,具有补气安神、止咳平喘等功效。灵芝主含氨基酸、多肽、蛋白质、真菌溶菌酶(fungal lysozyme),以及糖类(还原糖和多糖)、麦角甾醇、三萜类、香豆精甙、挥发油、硬脂酸、苯甲酸、生物碱、维生素B2及C等;孢子还含甘露醇、海藻糖(trehalose)等。在一些优选的实施方式中,所述灵芝提取物为灵芝多糖。
本申请中所述灵芝多糖的提取方法可为本领域技术人员熟知的任何一种,例如取灵芝子实体粉碎加入少量培养基发酵,发酵后原料离心,上清液低温真空浓缩,透析,乙醇沉淀,丙酮洗涤,除蛋白,喷雾干燥,即得。
黄芪,学名AstragaluspropinquusSchischkin,味甘,性温,归肺、脾经,具有补气固表、利尿脱毒、排脓、敛疮生肌等功效。黄芪根含2’,4’-二羟基-5,6-二甲氧基异黄酮(2’,4’-dihydroxy-5,6-dimethoxyisoflavone)、胆碱(choline)、甜菜碱(betaine)、氨基酸、蔗糖、葡萄糖醛酸及微量的叶酸。在一些优选的实施方式中,所述黄芪提取物为黄芪甲苷(CAS号:84687-43-4)。
黄柏,学名PhellodendronchinenseSchneid.,味苦,性寒,归肾、膀胱经,具有清热燥湿、泻火除蒸、解毒疗疮等功效。黄柏树皮含小檗碱、药根碱、木兰花碱、黄柏碱、N-甲基大麦芽碱、掌叶防己碱、蝙蝠葛碱等生物碱;另含黄柏酮、黄柏内酯、白鲜交酯、黄柏酮酸、青萤光酸、7-脱氢豆甾醇、β-谷甾醇、菜油甾醇。黄柏根皮含小檗碱、药根碱、黄柏碱、N-甲基大麦芽碱。
小球藻,学名Chlorella vulgaris,蛋白核小球藻含较多的维生素:硫胺素(thiamine),维生素(vitamin)B2、B6、B12,烟酰胺(nicotinamide),泛酸(pantothenicacid),胆碱(choline)。
茯苓,学名Poriacocos(Schw.)Wolf,味甘、淡,性平,归心、肺、脾、肾经,具有利水渗湿、健脾宁心等功效。茯苓菌核含β-茯苓聚糖约占干重93%和三萜类化合物乙酰茯苓酸、茯苓酸、3β-羟基羊毛甾三烯酸。此外,尚含树胶、甲壳质、蛋白质、脂肪、甾醇、卵磷脂、葡萄糖、腺嘌呤、组氨酸、胆碱、β-茯苓聚糖分解酶、脂肪酶、蛋白酶等。
紫草,学名RadixLithospermi,味甘、咸,性寒,归心、肝经,具有凉血、活血、解毒透疹等功效。紫草根含乙酰紫草醌、异丁酰紫草醌、β,β-二甲基丙烯紫草醌、β-羟基异戊酰紫草醌、3,4-二甲基戊烯-3-酰基紫草醌等。在一些优选的实施方式中,所述紫草提取物为紫草素(CAS号:517-89-5)。
在一些优选的实施方式中,所述植物提取物为灵芝多糖、或灵芝多糖与人参根提取物的混合。
灵芝多糖作为一种名贵的真菌类药物,在抗肿瘤、调节机体免疫功能等方面有着很好的药用价值。研究表明,灵芝中起作用的关键药效成分是灵芝多糖类化合物和灵芝三萜类化合物。发明人在研究中发现,在抗肿瘤的免疫机制中,灵芝并不通过直接杀死或抑制肿瘤细胞,而是通过增强人外周学淋巴细胞的免疫功能进而加强机体抗肿瘤功能。此外,灵芝还可以明显促进皮细胞的转化与增殖,增强巨噬细胞的吞噬作用,具备抗老、抗氧化的功能。灵芝多糖是由三股单糖链构成的、具有螺旋状立体构形(三级结构)的葡聚糖,其立体构形与脱氧核糖核酸(DNA)、核糖核酸(RNA)相似,正是由于特殊的构型才使得灵芝多糖具备药理活性,然而该构型隐藏了多糖的亲水基团,导致灵芝多糖的水溶性较差,适当的升温虽然可以提高灵芝多糖的水溶性,但灵芝多糖对温度敏感,升温会使多糖解构而失去活性。
本发明中所述灵芝多糖可为市售或自行提取,提取方法可为本领域技术人员熟知的任何一种,例如热水提取法、醇提法、碱提法、超声波酶提法等。
在一些优选的实施方式中,所述灵芝多糖的提取方法为超声波酶提法,包括以下步骤:
a.预处理:取赤芝药材,切成厚度为0.05~0.3cm的薄片;
b.超声波酶提取:向步骤a中的薄片加入重量为8~12倍的水,同时加入纤维素酶、木瓜蛋白酶,超声提取0.5~2小时,过滤,滤渣再次提取,合并两次滤液,即得。
发明人发现,使用上述方法提取得到的灵芝多糖收率和纯度较高,预处理将灵芝处理成薄片,控制了药材的吸水率的同时,保证多糖能够大量溶出,还能减少灵芝酸的溶出。发明人还发现,当灵芝多糖中含有1wt%左右的灵芝β-葡聚糖时,具有更高的生物活性,可渗透至表皮和真皮深层,起到免疫调节、增强活力、加速伤口愈合等效果。本发明中灵芝多糖的测定方法可为本领域技术人员熟知的任何一种,例如分光光度法或液相色谱法。
本发明中的人参根提取物作为一种免疫调节剂,在细胞信息传递中起重要作用,有助于防止肿瘤的生长,还可激活在防御、免疫、修复过程中起重要作用的上皮细胞、朗格汉斯细胞和巨噬细胞,促进自体EGF(人寡肽-1)的生成,抑制并治疗过敏反应,如接触性皮炎、尖锐湿疣和念珠菌感染。
本文中的术语“多肽”是α-氨基酸以肽键连接在一起而形成的化合物,是蛋白质水解的中间产物,由两个氨基酸分子脱水缩合而成的化合物叫做二肽,同理类推还有三肽、四肽、五肽等,通常由10~100个氨基酸分子脱水缩合而成的化合物叫多肽。
在一些优选的实施方式中,所述多肽选自抗菌肽、修复肽、细胞因子模拟肽、酶调节剂、激素肽中的一种或多种的混合;进一步优选的,所述多肽选自抗菌肽和修复肽的混合。
本文中的术语“抗菌肽”是指具有抗菌活性的多肽物质,对细菌有很强的杀伤作用。
在一些优选的实施方式中,所述抗菌肽选自昆虫抗菌肽、哺乳动物抗菌肽、两栖动物抗菌肽、植物抗菌肽、细菌抗菌肽中的一种或多种的混合;进一步优选的,所述抗菌肽为细菌抗菌肽。
在一些优选的实施方式中,所述细菌抗菌肽选自杆菌肽、短杆菌肽、多粘菌肽、乳链菌肽中的一种或多种的混合;进一步优选的,所述细菌抗菌肽为乳链菌肽。
在一些优选的实施方式中,所述抗菌肽中的氨基酸残基个数为20~60个;进一步优选的,所述抗菌肽中的氨基酸残基个数为30~50个;更进一步的,所述抗菌肽中的氨基酸残基个数为32~40个。
本文中的术语“氨基酸残基”是指多肽中的氨基酸单位,即由肽键链接的氨基酸失水后的剩余部分。本申请中氨基酸残基个数的测定方法可为本领域技术人员熟知的任何一种,例如使用多肽蛋白质测序仪进行测定。
抗菌肽作为一种天然、安全、高效杀菌剂,能够快速杀菌抑菌,5min内抗菌率高达95%以上,发明人发现,乳酸菌发酵产物(抗菌肽)带正电荷,在一定膜电位下,可吸附于病原菌细胞膜上,在细胞膜表面聚集,通过C末端作用插入细胞膜内形成通透性孔道,细胞膜失去极化,导致细胞内小分子溶质(ATP、氨基酸、离子等)流失,细胞外水分子流入,造成细胞膜内外能差消失,细胞自溶而死亡。发明人在研究中发现,当抗菌肽中的氨基酸残基个数在一定范围内时具有较优的杀菌效果,推测其原因在于,恰当的氨基酸残基个数能够保证抗菌肽分子横跨细胞膜形成完整的孔道,若残基个数过少,则无法穿透细胞膜,残基个数过多则有可能使分子出现缠绕,导致分子长度缩短。发明人还意料不到地发现,特定的抗菌肽能够促进灵芝多糖的溶解和吸收。
本文中的术语“修复肽”是指具有修复作用的多肽物质。
在一些优选的实施方式中,所述修复肽为去端酶小分子活性肽。
本发明所述去端酶小分子活性肽是指去端肽活性胶原,去掉两端的过敏原,提高其安全性的同时,保留了胶原蛋白的三螺旋分子结构,三条肽链互相盘绕形成右手复合螺旋,因此具有与胶原蛋白相似的生物活性,可被细胞膜受体识别,因此具有优异的生物相容性,能够参与介导细胞的粘附、迁移、分化、组织再生等生物过程,还具有极低的免疫原性,还可被生物降解成多肽和氨基酸,为细胞提供营养,维持新陈代谢,其特有的羟脯氨酸是人体组织启动修复和胶原合成的必需氨基酸。其可从动物皮或动物跟腱中提取得到,其提取方法可参考ZL201110361034.X、ZL200810045400.9等。
发明人发现,去端酶小分子活性肽作用在细胞活力层面:能够保护并激活线粒体,维持线粒体正常代谢、稳态、自嗜与凋亡,增强细胞活力与能量再生,ATP生成量提升110%,基础代谢率提升50%,该活性肽可以提升线粒体自身抗氧化能力,抑制活性氧、自由基与氧化应激,保护细胞,预防细胞与肌肤衰老维持细胞正常分化、信息传递、生长、周期与凋亡;同时在肌体功能层面:加速创伤愈合、炎症改善,快速修复损伤与修复皮肤屏障,改善皮肤微循环,促进毛细血管重建,缓解红血丝,对抗眼角膜损伤与口腔黏膜,阴道黏膜损伤。
在一些优选的实施方式中,所述抗菌肽和修复肽的重量比为(2~6):1;进一步优选的,所述抗菌肽和修复肽的重量比为(3~5):1。
在一些优选的实施方式中,所述植物提取物与多肽的重量比为(5~10):1;进一步优选的,所述植物提取物与多肽的重量比为(6~9):1。
发明人在研究中发现,通过抗菌肽、去端酶小分子活性肽、灵芝多糖等活性物的配合,调动人体的天然抗癌细胞能力,恢复机体内环境的平衡,增强基体的免疫系统,防止HPV16/18病毒颗粒通过基体表皮微小损伤进入,特异基因修饰细胞治疗,能针对HPV感染类型,特异调动HPV感染患者上皮细胞、免疫细胞及修复细胞功能,使得对抗细菌能力增强,可及时、靶向清除高危HPV病毒及感染细胞,预防组织高危HPV感染,纠正损伤细胞功能,对抗细胞癌变,从而防患于未然,预防阻断宫颈癌发生。发明人在研发过程中意外地发现,以特定的比例加入各活性物质,各原料的溶解性优异,能够形成均一体系长期保存,且活性不受影响。
本文中的术语“赋形剂”是指在药物制剂中除主药以外的附加物,尤指在药物混合物中有足够量液体情况下,为使混合物有粘性而加入的物质,对赋形剂的一般要求是性质稳定,与主要无配伍禁忌,不产生副作用,不影响疗效。
在一些优选的实施方式中,所述赋形剂选自壳聚糖、羟乙基纤维素、卡波姆、羟丙基甲基纤维素、明胶、海藻胶中的一种或多种的混合;进一步优选的,所述赋形剂选自壳聚糖、羟乙基纤维素、卡波姆中的一种或多种的混合;更进一步的,所述赋形剂为羟乙基纤维素。
本发明中的羟乙基纤维素可为市售,例如亚什兰生产的Natrosol系列产品。
在一些优选的实施方式中,所述敷料至少包括植物提取物50~90份、多肽5~15份、赋形剂5~10份、水30~40份。
本发明中所述水为纯化水或去离子水。
本发明提供的一种HPV病毒灭活敷料能够显著抑制和清除HPV病毒,阻断HPV再次感染。HPV病毒的基因结构如图2所示,其中E6、E7基因为HPV病毒主要致癌基因,过度表达E6/E7蛋白使细胞处于永生化的机制,因此沉默E6/E7的表达,干扰E6/E7基因的转录翻译,可达抗病毒、抗肿瘤的目的。本发明的抗病毒原理如图3所示,该敷料能够增强肌体免疫系统,修复表皮屏障,防止病毒颗粒进入人体;还能够增强抗细菌能力,破坏病菌细菌的细胞膜,使其自溶死亡;预防阻止高危险HPV感染,一方面组织病毒与细胞粘附结合,另一方面中断宿主细胞转录病毒mRNA;对抗细胞癌变,降低HPV16E6 mRNA、HPV18E7mRNA的表达水平,抑制E6、E7蛋白的表达,抑制H16阳性的H8细胞以及HPV18阳性的Hela细胞活性,促进细胞凋亡。
本发明的第二方面提供了一种如上所述的HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
实施例
下面结合具体实施例对本发明进行详细说明。以下实施例将有助于本领域的技术人员进一步理解本发明,但不以任何形式限制本发明。应当指出的是,对本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进。这些都属于本发明的保护范围。如无特殊说明,本发明中的原料均为市售。
实施例1
实施例1提供了一种HPV病毒灭活敷料,按重量份计,所述敷料包括植物提取物70份、多肽10份、赋形剂5份、水;所述植物提取物为灵芝多糖;所述多肽为乳链菌肽(氨基酸残基个数为34个)和去端酶小分子活性肽的混合,重量比为4:1;所述赋形剂为羟乙基纤维素,为亚什兰生产的Natrosol 250HBR。
所述灵芝多糖的提取方法包括以下步骤:
a.预处理:取赤芝药材,切成厚度为0.15cm的薄片;
b.超声波酶提取:取步骤a中的薄片50g,加入500g水,同时加入0.4g纤维素酶、0.3g木瓜蛋白酶,超声提取1.5小时,过滤,滤渣再次按照上述步骤提取,合并两次滤液,即得。
本例还提供了上述HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
实施例2
实施例2提供了一种HPV病毒灭活敷料,按重量份计,所述敷料包括植物提取物70份、多肽10份、赋形剂5份、水35份;所述植物提取物为灵芝多糖和人参根提取物的混合,重量比为5:2;所述多肽为乳链菌肽(氨基酸残基个数为34个)和去端酶小分子活性肽的混合,重量比为4:1;所述赋形剂为羟乙基纤维素,为亚什兰生产的Natrosol 250HBR。本例中灵芝多糖的提取方法与实施例1相同,人参根提取物亦采用相同方法提取。
本例还提供了上述HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
实施例3
实施例3提供了一种HPV病毒灭活敷料,按重量份计,所述敷料包括植物提取物70份、多肽10份、赋形剂5份、水;所述植物提取物为灵芝多糖;所述多肽为乳链菌肽(氨基酸残基个数为34个);所述赋形剂为羟乙基纤维素,为亚什兰生产的Natrosol 250HBR。本例中灵芝多糖的提取方法与实施例1相同。
本例还提供了上述HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
实施例4
实施例4提供了一种HPV病毒灭活敷料,按重量份计,所述敷料包括植物提取物70份、多肽10份、赋形剂5份、水;所述植物提取物为灵芝多糖;所述多肽为去端酶小分子活性肽;所述赋形剂为羟乙基纤维素,为亚什兰生产的Natrosol 250HBR。本例中灵芝多糖的提取方法与实施例1相同。
本例还提供了上述HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
实施例5
实施例5提供了一种HPV病毒灭活敷料,按重量份计,所述敷料包括植物提取物70份、多肽20份、赋形剂5份、水;所述植物提取物为灵芝多糖;所述多肽为乳链菌肽(氨基酸残基个数为34个)和去端酶小分子活性肽的混合,重量比为4:1;所述赋形剂为羟乙基纤维素,为亚什兰生产的Natrosol 250HBR。本例中灵芝多糖的提取方法与实施例1相同。
本例还提供了上述HPV病毒灭活敷料的制备方法,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
性能评价
1.对海拉细胞的抑制作用:使用实施例1中制得的HPV病毒灭活敷料处理海拉细胞,设置空白对照,并与市售抗HPV病毒产品对比,结果见图1,从图1可以得知,本发明实施例1能够显著抑制海拉细胞生长,促进海拉细胞的凋亡。本发明实施例2与实施例1的抗病毒效果类似。
2.对HPV16病毒的灭活测试:根据《消毒技术规范》2002版,使用实施例1中制得的HPV病毒灭活敷料进行灭活HPV病毒16型活性测试,实验细胞为293FT细胞,实验病毒为人乳头瘤病毒16型假病毒(HPV16pp),实验原理为含报告基因GFP的HPV假病毒颗粒感染293FT细胞后,感染细胞会表达绿色荧光蛋白,通过在荧光显微镜下观察表达GFP绿色荧光的细胞数目,可以反映出HPV病毒的感染情况,实验结果见表1。
表1
注:“+”表示有荧光斑点,“-”表示没有荧光斑点,“●”表示有细胞毒性,数值表示统计的每孔的荧光斑点数。
上述实验结果在细胞水平上检测了HPV病毒灭活敷料对HPV16型假病毒的灭活作用,检测结果显示病毒对照组病毒滴度为2.85*107ffu/ml,受检测样品HPV病毒灭活敷料组病毒滴度为2.7*106ffu/ml,相对于病毒对照组,受检测样品HPV病毒灭活敷料在室温1小时条件下对HPV16型假病毒滴度的降低为1.02log,灭活率为90.53%。
本发明实施例2与实施例1的抗病毒效果类似。
3.对HPV18病毒的灭活测试:根据《消毒技术规范》2002版,使用实施例1中制得的HPV病毒灭活敷料进行灭活HPV病毒18型活性测试,实验细胞为293FT细胞,实验病毒为人乳头瘤病毒18型假病毒(HPV18pp),实验原理为含报告基因GFP的HPV假病毒颗粒感染293FT细胞后,感染细胞会表达绿色荧光蛋白,通过在荧光显微镜下观察表达GFP绿色荧光的细胞数目,可以反映出HPV病毒的感染情况,实验结果见表2。
表2
注:“+”表示有荧光斑点,“-”表示没有荧光斑点,“●”表示有细胞毒性,数值表示统计的每孔的荧光斑点数。
上述实验结果在细胞水平上检测了HPV病毒灭活敷料对HPV18型假病毒的灭活作用,检测结果显示病毒对照组病毒滴度为8.01*107ffu/ml,受检测样品HPV病毒灭活敷料组病毒滴度为9.7*105ffu/ml,相对于病毒对照组,受检测样品HPV病毒灭活敷料在室温1小时条件下对HPV18型假病毒滴度的降低为1.92log,灭活率为98.79%。
本发明实施例2与实施例1的抗病毒效果类似。
4.相溶性测试:肉眼观察实施例1~5制得的HPV病毒灭活敷料,合格产品为无色透明敷料,若敷料中可观察到颗粒物则为不合格,本申请中实施例1、2均为合格产品,实施例3~5不合格。
由以上可以看出,本发明提供的敷料在对HPV病毒的抑制方面发挥着显著作用,通过抗菌肽、去端酶小分子活性肽、灵芝多糖等活性物在多靶点发挥作用,立足HPV发病机理,防止HPV16/18病毒颗粒通过基体表皮微小损伤进入来增强基体的免疫系统,并可以使得对抗细菌能力增强,可及时、靶向清除高危HPV病毒及感染细胞,预防组织高危HPV感染,纠正损伤细胞功能,对抗细胞癌变,预防阻断宫颈癌发生。此外,该敷料对革兰氏阳性球菌、阴性杆菌及真菌均有较强的杀菌作用,可刺激诱导阴道细胞产生低分子糖蛋白-内源性干扰素,活化巨噬细胞、NK细胞的生物活性,增强局部组织的抗病毒和机体免疫调节能力,防治阴道炎症:能有效地预防和快速治疗阴道炎、宫颈糜烂、白带恶臭、盆腔炎、附件炎,以及由于真菌感染的性病和慢性妇科疾病,还可修复宫颈糜烂,缩小糜烂面,促进宫颈糜烂面的愈合。
前述的实施例仅是说明性的,用于解释本发明所述方法的一些特征。所附的权利要求旨在要求可以设想的尽可能广的范围,且文本所呈现的实施例仅是根据所有可能的实施例的组合的选择的实施方式的说明。因此,申请人的用意是所附的权利要求不被说明本发明的特征的示例的选择限制。在权利要求中所用的一些数值范围也包括了在其范围之内的子范围,这些范围中的变化也应在可能的情况下解释为被所附的权利要求覆盖。
Claims (2)
1.一种HPV病毒灭活敷料,其特征在于,所述敷料至少包括植物提取物70份、多肽10份、赋形剂5份、水35份;
所述多肽选自抗菌肽和修复肽的混合;
所述抗菌肽和修复肽的重量比为4:1;
所述抗菌肽为细菌抗菌肽;
所述抗菌肽中的氨基酸残基个数为34个;
所述细菌抗菌肽为乳链菌肽;
所述修复肽为去端酶小分子活性肽;
所述植物提取物为灵芝多糖或灵芝多糖和人参根提取物的混合物;
所述灵芝多糖的提取方法包括以下步骤:
a.预处理:取赤芝药材,切成厚度为0.15cm的薄片;
b.超声波酶提取:取步骤a中的薄片50g,加入500g水,同时加入0.4g纤维素酶、0.3g木瓜蛋白酶,超声提取1.5小时,过滤,滤渣再次按照上述步骤提取,合并两次滤液,即得;
所述赋形剂羟乙基纤维素。
2.一种如权利要求1所述的HPV病毒灭活敷料的制备方法,其特征在于,包括以下步骤:将赋形剂与水混合后,加入植物提取物与多肽,即得。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011102513.5A CN112220739B (zh) | 2020-10-15 | 2020-10-15 | 一种hpv病毒灭活敷料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011102513.5A CN112220739B (zh) | 2020-10-15 | 2020-10-15 | 一种hpv病毒灭活敷料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112220739A CN112220739A (zh) | 2021-01-15 |
CN112220739B true CN112220739B (zh) | 2023-09-01 |
Family
ID=74111839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011102513.5A Active CN112220739B (zh) | 2020-10-15 | 2020-10-15 | 一种hpv病毒灭活敷料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112220739B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2758178A1 (en) * | 2003-08-01 | 2005-02-10 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
CN106474147A (zh) * | 2016-10-14 | 2017-03-08 | 上海颉隆投资管理有限公司 | 一种预防和控制人乳头状瘤病毒感染的敷料及其制备方法 |
CN107961265A (zh) * | 2017-12-19 | 2018-04-27 | 杨平芝 | 一种预防及抑制hpv病毒的妇科凝胶 |
CN110638893A (zh) * | 2019-10-28 | 2020-01-03 | 北京皓尔生物科技有限公司 | 一种抗hpv感染的药物组合物及其应用 |
CN111000890A (zh) * | 2019-12-30 | 2020-04-14 | 重庆宫妙生物科技有限公司 | 一种预防及抑制hpv病毒感染的凝胶敷料及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004007695A2 (en) * | 2002-03-08 | 2004-01-22 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
EP1660632B1 (en) * | 2003-08-01 | 2014-02-19 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
EP3081227A1 (en) * | 2015-04-15 | 2016-10-19 | Institut National De La Recherche Agronomique | Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics |
-
2020
- 2020-10-15 CN CN202011102513.5A patent/CN112220739B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2758178A1 (en) * | 2003-08-01 | 2005-02-10 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
CN106474147A (zh) * | 2016-10-14 | 2017-03-08 | 上海颉隆投资管理有限公司 | 一种预防和控制人乳头状瘤病毒感染的敷料及其制备方法 |
CN107961265A (zh) * | 2017-12-19 | 2018-04-27 | 杨平芝 | 一种预防及抑制hpv病毒的妇科凝胶 |
CN110638893A (zh) * | 2019-10-28 | 2020-01-03 | 北京皓尔生物科技有限公司 | 一种抗hpv感染的药物组合物及其应用 |
CN111000890A (zh) * | 2019-12-30 | 2020-04-14 | 重庆宫妙生物科技有限公司 | 一种预防及抑制hpv病毒感染的凝胶敷料及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN112220739A (zh) | 2021-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130337090A1 (en) | Plant extracts for treating burns and chronic wounds | |
KR102526210B1 (ko) | 매스틱검 추출 발효물을 유효성분으로 포함하는 피부재생 또는 피부 상처 개선용 화장료 조성물 및 이의 제조방법 | |
CN103462025A (zh) | 辅助降血脂的保健食品及其制备方法和应用 | |
CN112190593B (zh) | 一种抑制trpv1通路的多糖组合物及其制备方法和应用 | |
CN101647811A (zh) | 一种动物药的仿生酶解产物及其应用 | |
CN101020715B (zh) | 鹿茸神经生长因子(deer ngf)提取及其制备方法 | |
KR101966425B1 (ko) | 사이토메갈로바이러스 감염 장애를 치료하기 위한 의약 또는 건강 관리 제품의 제조에서의 인삼 추출물, 진세노사이드 및 진세노사이드 유도체의 용도 | |
KR20160064966A (ko) | 화학요법제 보조에 사용하는 의약 조성물 및 그 용도 | |
CN102526164A (zh) | 防治胰岛素抵抗及其相关代谢综合征的中药组合物 | |
CN109846896A (zh) | 常春藤皂苷在制备抗血管内皮细胞炎性损伤药物中的应用 | |
CN112057546A (zh) | 一种蜂胶灵芝孢子粉组合物及其制备方法和应用 | |
CN103301146B (zh) | 具有抗氧化、改善眼底血液循环作用的中药单体组合物 | |
CN105362295A (zh) | 一种治疗急慢性咽喉炎、口腔溃疡的美洲大蠊药物组合物及其制备方法 | |
KR20150014033A (ko) | 번데기동충하초 추출물을 유효성분으로 함유하는 간 기능 개선 기능성 식품조성물 및 그 제조방법 | |
US10086030B2 (en) | Use of composition in preparing health care products or medicines for preventing and treating allergic diseases | |
CN112220739B (zh) | 一种hpv病毒灭活敷料及其制备方法 | |
CN110664858B (zh) | 一种用于皮肤的青蒿提取物组合物、产品及其应用 | |
WO2007059685A1 (fr) | Calycosine d'astragalus a fonction de resistance contre le coxackievirus | |
CN110339234A (zh) | 一种用于治疗神经性耳鸣的含有大麻二酚的组合物及其制备方法 | |
CN107184815B (zh) | 一种治疗结核性溃疡、窦道的中药组合物及其制备方法和应用 | |
CN104524233B (zh) | 一种促进造血功能提高免疫力的生物反应调节剂及其制备与应用 | |
CN104840613A (zh) | 一种治疗原发性泡状棘球蚴病的药物组合物及其制备方法和用途 | |
CN103830262A (zh) | 一种抗癌辅助药物及其应用 | |
CN109096410A (zh) | 白花蛇舌草多糖在制备肠道菌群调节药物中的应用 | |
CN112675228B (zh) | 一种促进伤口愈合的软膏剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231011 Address after: 200444 Room 501, 502, 503, Floor 5, No. 11, Lane 2999, Hutai Road, Baoshan District, Shanghai Patentee after: Shanghai Borunke Biotechnology Co.,Ltd. Address before: 518116 unit 2202, block B, smart home, 76 Baohe Avenue, Baolong community, Baolong street, Longgang District, Shenzhen City, Guangdong Province Patentee before: GUORUN BIOTECHNOLOGY (SHENZHEN) Co.,Ltd. |